Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1b, Randomized, Blinded, Dose-Determined Study Evaluating the Safety and Tolerability Profile of Intervention With AT-100 (rhSP-D) in Preterm Neonates at High Risk for the Development of Bronchopulmonary Dysplasia (BPD)

NCT04662151 is registered in ClinicalTrials.gov with Airway Therapeutics, Inc. as lead sponsor.

NCT NCT04662151
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04662151 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1b, Randomized, Blinded, Dose-Determined Study Evaluating the Safety and Tolerability Profile of Intervention With AT-100 (rhSP-D) in Preterm Neonates at High Risk for the Development of Bronchopulmonary Dysplasia (BPD)
Lead sponsor
Airway Therapeutics, Inc.
Phase
Phase 1
Overall status
Completed
Start date
September 1, 2021
Completion date
May 29, 2024
Enrollment
37 (actual)
Sites
19

Conditions

As the registry lists them; a condition with its own page is linked.

bronchopulmonary dysplasia